442
Participants
Start Date
April 28, 2022
Primary Completion Date
August 4, 2023
Study Completion Date
August 4, 2023
PF-07852352 Influenza saRNA 1
Intramuscular injection
PF-07836391 Influenza saRNA
Intramuscular injection
PF-07836394 Influenza saRNA
Intramuscular injection
PF-07836395 Influenza saRNA
Intramuscular injection
PF-07836396 Influenza saRNA
Intramuscular injection
PF-07867246 Influenza saRNA
Intramuscular injection
Placebo
Intramuscular injection
Quadrivalent influenza vaccine (QIV)
Intramuscular injection
PF-07871987 Influenza saRNA
Intramuscular injection
PF-07914705 Influenza saRNA
Intramuscular injection
PF-07915048 Influenza saRNA
Intramuscular injection
NYU Langone Health, New York
SUNY Upstate Medical University Global Health Laboratory, Syracuse
SUNY Upstate Medical University Institute for Global Health, Syracuse
SUNY Upstate Medical University, Syracuse
Coastal Carolina Research Center, North Charleston
Panax Clinical Research, Miami Lakes
Pines Care Research Center, LLC, Pembroke Pines
Pinnacle Health Care Center, Pembroke Pines
Comprehensive Cardiology Consultants, Pembroke Pines
Mount Sinai Hospital, Miami Beach
Advanced Pharma CR, LLC, Miami
Miami Clinical Research, Miami
Finlay Medical Research, Greenacres City
CTI Clinical Research Center, Cincinnati
Great Lakes Clinical Trials - Andersonville, Chicago
Meridian Clinical Research, LLC, Omaha
Velocity Clinical Research, Omaha, Omaha
Pioneer Heart Institute, Lincoln
DM Clinical Research, Tomball
Benchmark Research, Austin
Eric S. Tiblier, MD, Austin
Arizona Heart Rhythm Center, Phoenix
Hope Research Institute, Phoenix
The Pain Center of Arizona, Phoenix
Diablo Clinical Research, Inc., Walnut Creek
Lead Sponsor
Pfizer
INDUSTRY